-
-
A BETA-3 ADRENERGIC AGONIST HAS BEEN APPROVED FOR the treatment of overactive bladder in adults. Mirabegron differs from other agents approved for this same indication, such as oxybutynin, tolterodine, solifenacin, darifenacin, etc., which are anticholinergic/antimuscarinic agents. Mirabegron is marketed by Astellas Pharma as Myrbetriq.
-
Clinical Briefs: Coffee Might be One Less Thing We Have to Worry About; ED, Lower Urinary Tract Symptoms, and Ejaculatory Dysfunction; The Allure of Shared Medical Appointments in Diabetes Care
-
In this study population with a 2% average risk of a major coronary event per year, LDL cholesterol, apolipoproteins, and LDL particle concentrations had similar and strong associations for major vascular events. The independent predictive value of HDL measures is less clear.
-
When routinely cultured, essentially all ICU privacy curtains were found to be contaminated with potential pathogens at least some of the time. Recovered organisms included methicillin-resistant staphylococci and vancomycin-resistant enterococci.
-
This study presents a large group of new cases of rhombencephalosynapsis and carefully describes correlations to other associated morphological abnormalities as well as to outcomes.
-
With the advent of specific genetic tests, atypical forms of facioscapulohumeral muscular dystrophy can be reliably diagnosed.
-
Vorapaxar is a potent antiplatelet medication with a novel action that works by inhibiting thrombin activation of platelets through the protease-activated receptor PAR-1.
-
-
Drug shortages; metformin and cancer prevention; migraine prevention guidelines; and FDA actions.
